CAMBRIDGE, Mass., April 12, 2018 /PRNewswire/ -- TCR2 Therapeutics Inc., an immuno-oncology company pioneeringa novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today that new preclinical data on its TRuC™ platform and its lead solid tumor program TC-210 will be presented at the American Association
The poster presentations will discuss rationales and mechanisms for the company's HLA-independent TRuC™-T cells and provide additional updates for TC-210, the company's lead program targeting mesothelin-positive solid tumors. TC-210 is advancing into the clinic later this year for solid tumor indications including ovarian, mesothelioma, cholangiocarcinoma, pancreatic and lung cancers. Abstracts are available on the AACR conference website at http://www.aacr.org.
About TCR2 TherapeuticsTCR2 Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies for solid tumors and blood cancers that utilize the full signaling power of complete T cell receptors (TCR) without the need for HLA-matching. TCR2's proprietary multi-format TRuC™ platform reprograms the natural TCR complex to elicit rapid killing of cancer cells with long persistence and low cytokine release. The company has demonstrated superior activity against several tumor targets in preclinical models compared to CAR T cells and will advance its lead solid tumor program TC-210 targeting mesothelin into the clinic in 2018. TCR2 was founded in 2015 by renowned German immunologist Dr. Patrick Baeuerle and now led by a world-class team of immunotherapy experts and entrepreneurs in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.
View original content:http://www.prnewswire.com/news-releases/tcr2-therapeutics-to-present-new-preclinical-data-at-the-american-association-for-cancer-research-aacr-2018-annual-meeting-300628614.html
SOURCE TCR2 Therapeutics
Subscribe to our Free Newsletters!